- Ionis Pharmaceuticals reported fourth-quarter revenue of $227 million, surpassing estimates of $137.3 million despite a 30% decline year-over-year.
- Commercial revenue increased by 8.9% year-over-year, totaling $86 million, slightly below the estimate of $87.4 million.
- TEGSEDI and WAYLIVRA net revenue was $8 million, down 11% from the previous year, and lower than the estimated $8.34 million.
- Royalties from SPINRAZA amounted to $64 million, marking a 3.2% increase year-over-year.
- R&D revenue saw a significant decrease of 43% year-over-year, generating $141 million.
- Amortization from upfront payments fell by 64% year-over-year, contributing $27 million.
- The adjusted net loss was $68 million, smaller than the estimated loss of $155 million but larger than the previous year’s loss of $17 million.
- Loss per share was 66 cents, better than the estimated loss of $1.13 per share but higher than the previous year’s loss of 6.0 cents per share.
- The company ended the period with $2.30 billion in cash and other resources, close to the estimate of $2.31 billion and down 1.4% year-over-year.
- Adjusted operating expenses amounted to $301 million, slightly higher than the estimate of $263.9 million but down 1.3% year-over-year.
- Ionis exceeded its 2024 financial guidance and plans three more independent launches over the next three years, including donidalorsen and olezarsen, subject to Phase 3 results.
- Market sentiment includes 17 buy ratings, 7 hold ratings, and 1 sell rating for Ionis Pharmaceuticals.
“`
Ionis Pharmaceuticals on Smartkarma
Smartkarma, the independent investment research platform, features insightful analyst coverage of Ionis Pharmaceuticals. One notable report by Baptista Research, led by an analyst named Baptista, expresses a bullish sentiment towards Ionis Pharmaceuticals. The report titled “Ionis Pharmaceuticals: Launch & Market Penetration of Olezarsen Driving Our Optimism! – Major Drivers” delves into the recent third-quarter financial results of Ionis Pharmaceuticals for 2024. It highlights key points such as upcoming product launches, ongoing clinical trials, and strategic pipeline developments. Of particular interest is the imminent launch of Olezarsen, a product targeting familial chylomicronemia syndrome (FCS), with FDA action expected soon.
A look at Ionis Pharmaceuticals Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 4 | |
| Resilience | 5 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Ionis Pharmaceuticals, Inc. operates in the biotechnology sector with a special focus on researching RNA-targeted drug discovery and development. Their primary goal is to create medications for individuals with unaddressed medical requirements. Looking at the Smartkarma Smart Scores for Ionis Pharmaceuticals, the company shows promise in terms of growth and resilience, scoring a solid 4 and 5 respectively. These high scores suggest a positive long-term outlook for Ionis Pharmaceuticals in terms of advancing its product pipeline and maintaining stability in the face of challenges.
While Ionis Pharmaceuticals demonstrates strength in growth and resilience, their scores in value, dividend, and momentum are more moderate. This indicates that although the company may have room for improvement in terms of valuation and momentum in the market, its solid growth and resilience factors position it well for a promising future. With a comprehensive focus on developing innovative drug solutions and catering to underserved medical needs, Ionis Pharmaceuticals appears poised to continue making progress in the biotechnology industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
